Barrett-Lee P - Search Results

1

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.

Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Hackshaw A, et al. Br J Cancer. 2005 Nov 28;93(11):1215-21. doi: 10.1038/sj.bjc.6602858. Br J Cancer. 2005. PMID: 16278665 Free PMC article.

2

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.

Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW. Jones AL, et al. Br J Cancer. 2009 Mar 10;100(5):684-92. doi: 10.1038/sj.bjc.6604909. Br J Cancer. 2009. PMID: 19259090 Free PMC article.

3

Growth factor expression in normal, benign, and malignant breast tissue.

Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powles TJ, Coombes RC. Travers MT, et al. Br Med J (Clin Res Ed). 1988 Jun 11;296(6637):1621-4. doi: 10.1136/bmj.296.6637.1621. Br Med J (Clin Res Ed). 1988. PMID: 3135043 Free PMC article.

4

Characterization of estrogen receptor messenger RNA in human breast cancer.

Barrett-Lee PJ, Travers MT, McClelland RA, Luqmani Y, Coombes RC. Barrett-Lee PJ, et al. Cancer Res. 1987 Dec 15;47(24 Pt 1):6653-9. Cancer Res. 1987. PMID: 3677099

5

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.

Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW. Barrett-Lee PJ, et al. Ann Oncol. 2009 May;20(5):816-27. doi: 10.1093/annonc/mdn728. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153118 Free article. Review.

6

Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy.

Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Barrett-Lee PJ, et al. Br J Cancer. 2000 Jan;82(1):93-7. doi: 10.1054/bjoc.1999.0883. Br J Cancer. 2000. PMID: 10638973 Free PMC article.

7

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy.

Barrett-Lee PJ. Barrett-Lee PJ. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S125-33. doi: 10.1677/erc.1.01024. Endocr Relat Cancer. 2005. PMID: 16113089 Review.

8

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group. Haviland JS, et al. Lancet Oncol. 2013 Oct;14(11):1086-1094. doi: 10.1016/S1470-2045(13)70386-3. Epub 2013 Sep 19. Lancet Oncol. 2013. PMID: 24055415 Clinical Trial.

9

Breast-cancer adjuvant therapy with zoledronic acid.

Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators. Coleman RE, et al. N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195. Epub 2011 Sep 25. N Engl J Med. 2011. PMID: 21995387 Free article. Clinical Trial.

10

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.

Bartlett JM, A'hern R, Piper T, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Bliss JM, Ellis P, Barrett-Lee PJ. Bartlett JM, et al. Breast Cancer Res Treat. 2013 Apr;138(3):773-81. doi: 10.1007/s10549-013-2489-y. Epub 2013 Mar 28. Breast Cancer Res Treat. 2013. PMID: 23535839 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results